

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Marc Elsayed, et al. Confirmation No.: Not Yet Assigned

Application No.: 10/762,897 Group Art Unit: Not Yet Assigned

Filing Date: January 22, 2004 Examiner: Not Yet Assigned

For: METHODS FOR DELIVERING A DRUG TO A PATIENT WHILE

PREVENTING THE EXPOSURE OF A FOETUS OR OTHER

CONTRAINDICATED INDIVIDUAL TO THE DRUG

DATE OF DEPOSIT: March 18, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 2213 1450

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified	application as set forth in § 1.491, before the mailing date			
of a first Office A	ction on the merits of the above-identified application, or			
before the mailing	date of a first Office Action after the filing of request for			
continued examinat	ion under § 1.114, no additional fee is required.			
In accordance with	§ 1.129(a), this Information Disclosure Statement is being			
filed in connection	with the first or second After Final Submission			
therefore:				
Cert	fication in Accordance with § 1.97(e) is attached; or			
The	fee of \$180.00 as set forth in § 1.17(p) is attached.			
In accordance with § 1.97(c), this Information Disclosure Statement is being				
filed after the period set forth in § 1.97(b) above but before the mailing date of				
either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or				
before an action tha	t otherwise closes prosecution in the application, therefore:			
	Certification in Accordance with § 1.97(e) is attached			
	or			
	The fee of \$180.00 as set forth in § 1.17(p) is attached.			
In accordance with § 1.97(d), this Information Disclosure Statement is being				
filed after the mailing date of either a Final Action under § 1.113 or a Notice				
of Allowance under § 1.311 but before, or simultaneously with, the paymen				
of the Issue Fee, therefore included are: Certification in Accordance with				
1.97(e); and the submission fee of $$180.00$ as set forth in § 1.17(p).				
Copies of each of	the references listed on the attached Form PTO-1449 are			
analogad haravvith				

DOCKET NO.: CELG-0401 - 3 -**PATENT** \boxtimes Copies of references listed on the attached Form PTO-1449 are enclosed herewith Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i). **EXCEPT THAT:** In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. \bowtie In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application: 冈 Copies of references 1-4 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/143,569, filed August 28, 1998 now U.S. Patent No. 6,045,501; copies of

references 5-8 listed on the attached Form PTO-1449 were

previously cited by or submitted to the Patent and Trademark

Office in prior Application No. 09/479,682, filed January 7,

2000; copies of references 9-18 listed on the attached Form

PTO-1449 were previously cited by or submitted to the Patent

and Trademark Office in prior Application No. 09/964,068,

filed September 26, 2001 now U.S. Patent No. 6,561,976.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-

3050. This form is submitted in duplicate.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.


Date: 3/18/04

Angela Verrecchio Registration No. 54,510

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW



ZZZZ KIVILI VIZI				DATE CONSIDER			
EXAMINER				DATE CONSIDER	RED		
	18	WO 00/51053	08/31/00	PCT			
	17	WO 99/10829	03/04/99	PCT			
rmitiai	16	WO 98/13783	04/02/98	PCT	YES	NO	
Examiner Initial		Document No.	Date	Country	YES	Translation	
		FOR	EIGN PATH	ENT DOCUMENTS			
			-				
		1103	Dute	Transc		Subcluss	
Examiner Initial		Document No.	Date	Name	Class	Subclass	
		U.	S. PATENT	T DOCUMENTS	1		
				Confirmation No. Not Yet Assigned			
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Filing Date January 22, 2004	Group Not Yet Assigned		
				Applicant Marc Elsayed, et al.			
Form PTO-1449 Modified				Docket No. CELG-0401	Application No. 10/762,897		



Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Docket No. Application No. CELG-0401 10/762,897

Applicant

Marc Elsayed, et al.

Filing Date January 22, 2004

Confirmation No. Not Yet Assigned

Group

Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner	·	Document				
Initial		No.	Date	Name	Class	Subclass
	1	5,299,121	03/20/94	Brill, et al.	600	301
	2	5,594,637	01/14/97	Eisenberg, et al.	600	300
	3	5,619,991	04/15/97	Sloane	600	300
	4	5,660,176	08/26/97	Iliff	600	300
	5	5,845,255	12/01/98	Mayaud	705	3
	6	6,014,631	01/11/00	Teagarden, et al.	705	3
	7	6,055,507	04/25/00	Cunningham	705	3
	8	6,128,620	10/03/00	Pissanos, et al.	707	102
	9	5,619,991	04/15/97	Sloane	128	630
	10	5,974,203	10/26/99	Tadokoro, et al.	382	309
	11	6,045,501	04/04/00	Elsayed, et al.	600	300
	12	6,063,026	05/16/00	Schauss, et al.	600	300
	13	6,131,090	10/10/00	Basso, Jr., et al.	706	23
	14	6,202,923 B1	03/20/01	Bayer, et al.	235	375
	15	6,315,720 B1	11/13/01	Williams, et al.	600	300
				·		
EXAMINER				DATE CONSIDEREI	<u> </u>	